VITA-FAST is a unique ERC-20 token developed by VitaDAO, a decentralized autonomous organization focused on advancing longevity research. Built on the Ethereum blockchain, these tokens represent fractional ownership of an Intellectual Property Non-Fungible Token (IP-NFT) derived from pioneering research conducted at the Korolchuk Lab, Newcastle University. By holding VITA-FAST tokens, investors gain governance rights over the intellectual property, enhancing participation in decision-making processes related to scientific advancements. The main goal of this project is to identify and develop therapeutic compounds capable of reactivating autophagy in Npc1 -/- cells, which is essential for addressing the challenges posed by Niemann-Pick Type C disease. The research employs advanced screening techniques to evaluate bioactive and commercial small molecules, aiming to pinpoint effective autophagy activators that do not exhibit cytotoxicity. What sets VITA-FAST apart is its innovative methodology for discovering new compounds that promote autophagy in specific cell types. The project utilizes high-throughput screening methods and sophisticated assays, enabling the exploration of a diverse range of chemical compounds. This approach seeks to uncover novel treatments that differ significantly from existing autophagy inducers, potentially leading to breakthrough therapies. Under the guidance of Dr. Korolchuk and his dedicated team, the project has made significant strides, moving from initial data collection on thousands of compounds to identifying promising lead compounds with autophagic properties. The initiative is advancing towards drug translation, including studies on pharmacokinetics and scalability. Future efforts will focus on screening third-generation compounds and conducting both in vitro and in vivo testing using patient-derived models, which will further develop the understanding of the therapeutic potential of these compounds in treating Niemann-Pick Type C disease.